ERBB2 Promoter Binding Protein In Neoplastic Disease
Description of Invention:
Isolation of a novel ERBB2 promotor binding protein offers to improve the diagnosis and, specifically, the detection and monitoring of neoplastic diseases. This invention has particular application for the early detection of breast cancer. The HER-2/neu (ERBB2/c-erbB-2), or ERBB2, gene sequence appears to be one of the primary genes responsible for the transition of normal epithelial cells toward carcinoma and the subsequent development of invasive and metastatic cancer. For women, early detection of breast cancer is crucial for survival; however, by the time the gene product of ERBB2 is measurable by current methods, the prognosis of patients is not good. This invention improves on earlier methods for detecting and treating breast cancer by providing a purified and isolated DNA binding protein that specifically binds to the promoter region of the c-ERBB2 (HER-2/neu) gene sequence (hence the term HER-2 promoter binding protein, HPBF). Antibodies specific for this DNA binding protein, called HPBF, can be used to assay for the presence of HPBF in a biological sample and, thus, detect the presence of cancer. The purified HPBF also can be used to test the ability of substances to inhibit the activity of HPBF and thus potentially halt or reverse growth of the cancer. This invention includes antisense nucleotides that effectively prevent HPBF from binding to the promoter.
Inventors:
Raziuddin and F Sarkar (NCI)
Patent Status:
DHHS Reference No. E-184-1993/0 --
U.S. Patent 5,518,885 issued 21 May 1996
U.S. Patent 5,654,406 issued 05 Aug 1997
Portfolios: Cancer
Cancer -Diagnostics-In Vitro-DNA Based Cancer -Therapeutics-Gene Therapy-Genes Cancer -Therapeutics-Biological Response Modifiers-Growth Factors Cancer -Diagnostics Cancer -Therapeutics
For Additional Information Please Contact: Susan S. Rucker J.D.
NIH Office of Technology Transfer
6011 Executive Blvd, Suite 325
Rockville, MD 20852-3804
Phone: (301) 435-4478
Email: ruckersu@mail.nih.gov
Fax: (301) 402-0220
